Elevation Oncology Inc [NASDAQ: ELEV] slipped around -1.35 points on Tuesday, while shares priced at $0.78 at the close of the session, down -63.37%.
Compared to the average trading volume of 742.47K shares, ELEV reached a trading volume of 19200177 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What do top market gurus say about Elevation Oncology Inc [ELEV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ELEV shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ELEV stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Elevation Oncology Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 31, 2024. While these analysts kept the previous recommendation, Stephens raised their target price to Overweight. The new note on the price target was released on May 14, 2024, representing the official price target for Elevation Oncology Inc stock. Previously, the target price had yet another raise to $7, while JMP Securities analysts kept a Mkt Outperform rating on ELEV stock. On May 30, 2023, analysts increased their price target for ELEV shares from 5 to 8.
The Average True Range (ATR) for Elevation Oncology Inc is set at 0.33 The Price to Book ratio for the last quarter was 0.53, with the Price to Cash per share for the same quarter was set at 1.90.
How has ELEV stock performed recently?
Elevation Oncology Inc [ELEV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -71.63. With this latest performance, ELEV shares dropped by -72.04% in over the last four-week period, additionally sinking by -73.73% over the last 6 months – not to mention a drop of -20.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ELEV stock in for the last two-week period is set at 16.68, with the RSI for the last a single of trading hit 10.82, and the three-weeks RSI is set at 21.57 for Elevation Oncology Inc [ELEV]. The present Moving Average for the last 50 days of trading for this stock 2.95, while it was recorded at 2.09 for the last single week of trading, and 2.64 for the last 200 days.
Elevation Oncology Inc [ELEV]: Deeper insight into the fundamentals
Elevation Oncology Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 46.22 and a Current Ratio set at 46.22.
Insider trade positions for Elevation Oncology Inc [ELEV]
The top three institutional holders of ELEV stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in ELEV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in ELEV stock with ownership which is approximately 5.1238%.
